11th Jan 2021 07:00
Notice of Interim Results
Oxford, UK; 11 January 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the Clinical AI company, will announce its Interim Results for the 6 months ended 31 October 2020 on Thursday 21 January 2021.
Lord (Paul) Drayson, Chief Executive Officer, and Michael Norris, Interim Chief Financial Officer, will host a virtual briefing for analysts and investors at 13:00 GMT on the day of the results.
Details of the webcast, and the presentation slides, will be available via the Company website. For more details please contact [email protected].
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com) | +44 (0) 330 058 1845 |
Lord (Paul) Drayson PhD FREng, Chief Executive Officer |
|
Michael Norris, Interim Chief Financial Officer
Dr Richard Pye, Chief Investment Officer |
|
Peel Hunt LLP (Nominated Adviser and Joint Broker) | + 44 (0) 20 7418 8900 |
Dr Christopher Golden |
|
James Steel |
|
Oliver Jackson |
|
Liberum (Joint Broker) | + 44 (0) 20 3100 2000 |
Bidhi Bhoma |
|
Euan Brown |
|
Consilium Strategic Communications | +44 (0) 7780600290 |
Mary-Jane Elliott |
|
Sukaina Virji |
|
Davide Salvi |
|
|
About Sensyne Health
Sensyne Health plc is a clinical AI company that works in partnership with global healthcare organisations to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com
Related Shares:
SENS.L